Virological Response to Highly Active Antiretroviral Therapy Is Unaffected by Antituberculosis Therapy
Author(s) -
Ronan Breen,
Robert F. Miller,
T Gorsuch,
Colette Smith,
Jonathan Ainsworth,
Jayne Ballinger,
Leonie Swaden,
Ian Cropley,
Margaret Johnson,
Marc Lipman
Publication year - 2006
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/503437
Subject(s) - tuberculosis , medicine , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , viral load , viral disease , population , sida , virology , virus , coinfection , lentivirus , pathology , environmental health
We compared 156 human immunodeficiency virus (HIV)-infected patients who had tuberculosis with control populations of similar size. Of 111 patients with HIV infection and tuberculosis who received highly active antiretroviral therapy (HAART) and therapy for tuberculosis concurrently, 92 (83%) achieved or maintained virus loads of <50 copies/mL, and 99 (89%) achieved or maintained a >or=2 log10 reduction in virus load after 6 months. Virological response and changes in CD4 cell count were equivalent to those in 111 matched HIV-infected subjects without tuberculosis starting HAART. Tuberculosis recurrence rates were similar to those found in an HIV-uninfected population of 156 subjects (3% and 1%, respectively). Treatment for HIV and tuberculosis does not compromise outcomes for either disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom